肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：PAM50可以为晚期乳腺癌患者提供预后信息

2017-12-03 MedSci MedSci原创

乳腺癌PAM50预后
关注

乳腺癌转移转录通路活化及相关分子亚型已被证明可以显着影响患者复发后生存。CLIN CANCER RES近期发表了一篇文章，研究晚期乳腺癌临床常用的基因特征的意义。

乳腺癌转移转录通路活化及相关分子亚型已被证明可以显着影响患者复发后生存。CLIN CANCER RES近期发表了一篇文章，研究晚期乳腺癌临床常用的基因特征的意义。

作者通过细针穿刺活检获得109例远处转移或无法手术的局部复发晚期乳腺癌组织并通过表达谱分析。评估所有转移灶的基因特征（GGI，70基因，复发评分，细胞周期评分，复发风险评分和PAM50），及其与长期（5年）或短期（1.5年）复发后生存之间的关系。研究结果表明，综合所有特征后大部分转移都归类为中度风险或高度风险组，转移性特征亚组与原发肿瘤雌激素受体状态和病理分级具有显着相关性。当考虑所有转移部位时，只有PAM50在K-M分析时具有统计学显着意义。这一显着性在仅分析淋巴结转移的单变量和多变量分析的模型中依然存在，联合其他转移部位分析时依然有类似倾向，但是未达到统计学显着意义。

文章最后认为，该研究结果第一次证明PAM50基因特征可以为淋巴结转移晚期乳腺癌患者提供预后信息。

原始出处：
Nicholas P.Tobin,Arian Lundberg,et al.PAM50 Proviedes Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.CLIN CANCER RES.December 2017 doi:10.1158/1078-0432.CCR-17-2301

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717832, encodeId=c3061e17832de, content=<a href='/topic/show?id=4213136992c' target=_blank style='color:#2F92EE;'>#PAM50#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13699, encryptionId=4213136992c, topicName=PAM50)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af4632462415, createdName=kzlchina, createdTime=Thu Nov 15 00:34:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267199, encodeId=19b426e199f1, content=学习了不少事情!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 06 08:03:15 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571091, encodeId=913015e10912a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Dec 04 23:34:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266664, encodeId=c1562666643d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Dec 04 07:46:02 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266421, encodeId=4c77266421f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Dec 03 09:33:40 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2018-11-15 kzlchina

    #PAM50#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1717832, encodeId=c3061e17832de, content=<a href='/topic/show?id=4213136992c' target=_blank style='color:#2F92EE;'>#PAM50#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13699, encryptionId=4213136992c, topicName=PAM50)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af4632462415, createdName=kzlchina, createdTime=Thu Nov 15 00:34:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267199, encodeId=19b426e199f1, content=学习了不少事情!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 06 08:03:15 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571091, encodeId=913015e10912a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Dec 04 23:34:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266664, encodeId=c1562666643d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Dec 04 07:46:02 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266421, encodeId=4c77266421f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Dec 03 09:33:40 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-06 圣艮山

    学习了不少事情!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1717832, encodeId=c3061e17832de, content=<a href='/topic/show?id=4213136992c' target=_blank style='color:#2F92EE;'>#PAM50#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13699, encryptionId=4213136992c, topicName=PAM50)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af4632462415, createdName=kzlchina, createdTime=Thu Nov 15 00:34:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267199, encodeId=19b426e199f1, content=学习了不少事情!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 06 08:03:15 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571091, encodeId=913015e10912a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Dec 04 23:34:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266664, encodeId=c1562666643d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Dec 04 07:46:02 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266421, encodeId=4c77266421f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Dec 03 09:33:40 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-04 hanhaisha2013

    #乳腺癌患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1717832, encodeId=c3061e17832de, content=<a href='/topic/show?id=4213136992c' target=_blank style='color:#2F92EE;'>#PAM50#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13699, encryptionId=4213136992c, topicName=PAM50)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af4632462415, createdName=kzlchina, createdTime=Thu Nov 15 00:34:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267199, encodeId=19b426e199f1, content=学习了不少事情!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 06 08:03:15 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571091, encodeId=913015e10912a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Dec 04 23:34:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266664, encodeId=c1562666643d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Dec 04 07:46:02 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266421, encodeId=4c77266421f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Dec 03 09:33:40 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-04 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1717832, encodeId=c3061e17832de, content=<a href='/topic/show?id=4213136992c' target=_blank style='color:#2F92EE;'>#PAM50#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13699, encryptionId=4213136992c, topicName=PAM50)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af4632462415, createdName=kzlchina, createdTime=Thu Nov 15 00:34:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267199, encodeId=19b426e199f1, content=学习了不少事情!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Wed Dec 06 08:03:15 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571091, encodeId=913015e10912a, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Dec 04 23:34:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266664, encodeId=c1562666643d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Dec 04 07:46:02 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266421, encodeId=4c77266421f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Dec 03 09:33:40 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

Obes Rev：体重与乳腺癌风险

研究认为，总体上体重增加可降低女性乳腺癌风险，但对于30岁以下女性人群，过早的体重增加导致其绝经后乳腺癌风险增加。这些发现进一步证明了在一生中保持稳定体重的必要性

ANN ONCOL：基因改变与乳腺癌放疗抵抗

预后特征相似的乳腺癌患者最终的临床结局异质性很大，其中部分原因可能与放疗抵抗导致的局部复发有关。ANN ONCOL近期发表了一篇文章，研究乳腺癌局部复发的预测性分子标志

Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。

HER2靶向治疗在新辅助、辅助治疗甚至已发生转移的情况下，均可提高HER2阳性的乳腺癌患者的预但部分患者在疾病早期进行治疗后多年里仍有复发或死亡的风险。

凌瑞教授：泛西北乳腺癌-高地论坛，努力提高西北地区乳腺癌规范化诊治水平

2017年11月18日，古城西安迎来了第五届泛西北乳腺癌-高地论坛的成功举办。本次“高地论坛”受到西北地区乳腺癌同道的高度关注，现场学术讨论气氛热烈。会后《肿瘤瞭望》有幸采访了大会主席、空军军医大学西京医院凌瑞教授。凌教授盘点了“高地论坛”的会议亮点，对提高西北地区乳腺癌规范化诊疗水平提出了展望。

马斌林教授：新疆地区乳腺癌的诊疗现状和心得体会

乳腺癌作为女性发病率和死亡率最高的恶性肿瘤，其诊疗水平的提高有助于改善患者的生存预后以及减轻患者的社会负担。乳腺癌在不同地区的诊疗水平相差较大，近年来，新疆地区在乳腺癌的诊疗过程、诊疗水平上取得了优异的成绩。今天，【肿瘤资讯】有幸邀请到新疆医科大学附属肿瘤医院的马斌林教授为我们分享新疆地区的乳腺癌诊疗现状和心得体会。

ANN ONCOL：多西他赛治疗时间对临床结果的影响

帕妥珠单抗，曲妥珠单抗和多西他赛联合治疗是HER2阳性转移性乳腺癌标准一线治疗方案。CLEOPATRA临床研究主要评估在这一治疗方案中多西他赛治疗时间对临床效果的影响。该研究也对不同多西他赛治疗时间内帕妥珠单抗和曲妥珠单抗的临床获益进行评估。